Clinical Trial Update: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Inetetamab plus Pyrotinib and chemotherapy for previously untreated HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Inetetamab (inetetamab)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Fujian Medical University | Conditions: HER2-positive Recurrent/Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN